Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 14/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096167 | 0.93 | MAPK14 (0.52) | GHSRMAPK14DRD2DRD3 | |
| SCHEMBL5925665 | 0.84 | GHSR (0.51) | GHSRMAPK14DRD2DRD3KDM4E | |
| SCHEMBL5925669 | 0.82 | GHSR (0.56) | GHSRMAPK14HPGD | |
| SCHEMBL3249536 | 0.81 | GHSR (0.64) | GHSRMAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL6096974 | 0.79 | GHSR (0.57) | GHSRMAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL5276413 | 0.78 | MAPK14 (0.53) | MAPK14ALDH1A1 | |
| SCHEMBL5273569 | 0.78 | HCRTR1 (0.40) | MAPK14ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL27574061 | 0.78 | GHSR (0.56) | GHSRMAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL6097439 | 0.78 | GHSR (0.53) | GHSRMAPK14DRD2DRD3KDM4E | |
| SCHEMBL6094856 | 0.78 | MAPK14 (0.51) | GHSRMAPK14DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448201-B1 | N-(INDOLCARBONYL-)PIPERAZINE DERIVATIVES FOR THE TREATMENT OF OBESITY | MERCK PATENT GMBH (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-7084143-B2 | N-(indolecarbonyl) piperazine derivatives | MERCK PATENT GMBH (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20060040951-A1 | Use of 5-ht2 receptor antagonists for the treatment of sleep disorders | MERCK PATENT GMBH (DE) | 2006-02-23 | — | — | US | disclosed |
| US-20050014766-A1 | Use of n-(indolecarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-6838461-B1 | N-(indolcarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-04 | — | — | US | disclosed |
| EP-1198453-B9 | N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-11-10 | — | — | EP | disclosed |
| EP-1198453-B1 | N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014766-A1 | Use of n-(indolecarbonyl-)piperazine derivatives | GPR119, CHRM1, HTR1A | GHSR 279/4885MAPK14 4344/4885DRD2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.